brd1652

Description: BRD-1652 is a novel, highly potent and selective glycogen synthase kinase 3 (GSK3) inhibitor. It has a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. BRD1652 demonstrated in vivo efficacy in a dopaminergic signaling paradigmmodeling mood-related disorders. These new chemical probes open the wayfor exclusive analyses of the function of GSK3 kinases in multiplesignaling pathways involved in many prevalent disorders. GSK3 comprises two highly similar paralogs, GSK3alpha and GSK3beta, which arekey regulatory kinases in the canonical Wnt pathway. GSK3 stands as anodal target within this pathway and is an attractive therapeutic targetfor multiple indications. Despite being an active field of research forthe past 20 years, many GSK3 inhibitors demonstrate either poor tomoderate selectivity versus the broader human kinome or physicochemicalproperties unsuitable for use in in vitro systems or in vivo models.

References: ACS Chem Biol. 2016 Jul 15; 11(7):1952-63